Frazier Healthcare Partners closed Frazier Life Sciences IX, its ninth institutional fund and second dedicated life sciences vehicle, on $419 million after a three-month fundraise.
The fund, which was oversubscribed, will focus on early-stage investments in therapeutics companies developing biopharmaceuticals.
According to the firm’s press release, Frazier’s life sciences team will allocate two-thirds of its portfolio to series A and seed investments.
The Menlo Park-based firm’s predecessor life sciences fund, Frazier Life Sciences VIII, closed on $262 million in 2015.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: